Enfusion Q1 2024 Adj EPS $0.06 Beats $0.04 Estimate, Sales $48.052M Beat $47.616M Estimate
Portfolio Pulse from Benzinga Newsdesk
Enfusion (NYSE:ENFN) reported Q1 2024 adjusted EPS of $0.06, surpassing the $0.04 estimate, and sales of $48.052M, exceeding the $47.616M estimate. This represents a 100% increase in EPS and a 17.28% increase in sales from the same period last year.
May 09, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enfusion reported a significant beat on both EPS and sales estimates for Q1 2024, with a 100% increase in EPS and a 17.28% increase in sales year-over-year.
The substantial beat on both earnings per share and sales estimates, coupled with significant year-over-year growth, is likely to positively impact investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100